Chimeric Interferon Antibody Conjugate for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in effectively enhancing the immunogenicity of tumor cells and targeting scattered micrometastatic tumor deposits, while interferon-alpha's therapeutic potential is limited by its short half-life and systemic toxicity.
Innovation Solution
A chimeric construct comprising an interferon attached to a targeting moiety, such as an antibody that specifically binds to a tumor-associated antigen, using a proteolysis-resistant peptide linker, to improve therapeutic efficacy and reduce systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-alpha is used as a therapeutic agent, then antitumor activity is improved, but systemic toxicity increases and half-life decreases
Solution Approach 1:
The patent applies local quality by conjugating interferon-alpha to an antibody that specifically targets tumor-associated antigens. This creates a heterodimeric molecule where the interferon component exerts its antitumor effect locally at the tumor site while the antibody component provides targeted delivery, reducing systemic distribution and toxicity.
Solution Approach 2:
The antibody acts as an intermediary that mediates the delivery of interferon-alpha to tumor cells. The antibody binds to tumor-associated antigens and carries the interferon-alpha to the target site, enabling selective delivery and reducing the need for high systemic doses that cause toxicity.
2Reliability
If interferon-alpha is used as a therapeutic agent, then antitumor activity is improved, but half-life decreases
Solution Approach 1:
The patent merges interferon-alpha with an antibody to form a heterodimeric conjugate. This combination leverages the long half-life and stability of the antibody component to extend the duration of action of the interferon-alpha, while maintaining its antitumor activity through the preserved interferon domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric construct effectively inhibits tumor cell growth and proliferation, achieving potent antitumor activity with reduced systemic toxicity, as demonstrated by the attachment of interferon-alpha to antibodies like anti-HER2/neu IgG3, leading to improved in vivo half-life and therapeutic index.
Implementation Method 1
an antibody that is an intact immunoglobulin that specifically binds to a CD33 tumor associated antigen
Implementation Method 2
the antibody is attached to the interferon by a proteolysis resistant peptide linker
Implementation Method 3
wherein the construct when contacted to a tumor cell results in the killing or inhibition of growth or proliferation of the tumor cell
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-α).